Autophagy as a molecular target for cancer treatment
Autophagy is an evolutionarily conserved catabolic mechanism, by which eukaryotic cells
recycle or degrades internal constituents through membrane-trafficking pathway. Thus …
recycle or degrades internal constituents through membrane-trafficking pathway. Thus …
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Y Wang, B Deng - Cancer and Metastasis Reviews, 2023 - Springer
Hepatocellular carcinoma (HCC) is a common malignancy and one of the leading causes of
cancer-related death. The biological process of HCC is complex, with multiple factors …
cancer-related death. The biological process of HCC is complex, with multiple factors …
Management of adverse events associated with tyrosine kinase inhibitors: improving outcomes for patients with hepatocellular carcinoma
L Rimassa, R Danesi, T Pressiani, P Merle - Cancer Treatment Reviews, 2019 - Elsevier
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer.
Sorafenib, regorafenib, lenvatinib and cabozantinib are tyrosine kinase inhibitors (TKIs) that …
Sorafenib, regorafenib, lenvatinib and cabozantinib are tyrosine kinase inhibitors (TKIs) that …
[HTML][HTML] Chemotherapy for hepatocellular carcinoma: The present and the future
M Le Grazie, MR Biagini, M Tarocchi… - World journal of …, 2017 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver. Its
relationship to chronic liver diseases, in particular cirrhosis, develops on a background of …
relationship to chronic liver diseases, in particular cirrhosis, develops on a background of …
[HTML][HTML] Challenges of advanced hepatocellular carcinoma
S Colagrande, AL Inghilesi, S Aburas… - World journal of …, 2016 - ncbi.nlm.nih.gov
Hepatocellular carcinoma (HCC) is an aggressive malignancy, resulting as the third cause
of death by cancer each year. The management of patients with HCC is complex, as both the …
of death by cancer each year. The management of patients with HCC is complex, as both the …
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
M Reig, F Torres, C Rodriguez-Lope, A Forner… - Journal of …, 2014 - Elsevier
Background & Aims There are no clinical data/markers to predict improved survival in
patients with hepatocellular carcinoma treated with sorafenib. Majority of sorafenib adverse …
patients with hepatocellular carcinoma treated with sorafenib. Majority of sorafenib adverse …
The adverse effects of sorafenib in patients with advanced cancers
Y Li, ZH Gao, XJ Qu - Basic & Clinical Pharmacology & …, 2015 - Wiley Online Library
Sorafenib is the first multi‐kinase inhibitor (TKI) approved for the treatment of advanced
hepatocellular cancer (HCC) and metastatic renal cell cancer (RCC) and is increasingly …
hepatocellular cancer (HCC) and metastatic renal cell cancer (RCC) and is increasingly …
Role of ferroptosis in non-alcoholic fatty liver disease and its implications for therapeutic strategies
H Zhang, E Zhang, H Hu - Biomedicines, 2021 - mdpi.com
Non-alcoholic fatty liver disease (NAFLD) has become the chronic liver disease with the
highest incidence throughout the world, but its pathogenesis has not been fully elucidated …
highest incidence throughout the world, but its pathogenesis has not been fully elucidated …
[HTML][HTML] Tyrosine kinase inhibitors
RJ Thomson, M Moshirfar, Y Ronquillo - StatPearls [Internet], 2023 - ncbi.nlm.nih.gov
Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf US flag An official website of the
United States government Here's how you know NIH NLM Logo Access keys NCBI Homepage …
United States government Here's how you know NIH NLM Logo Access keys NCBI Homepage …
Treatment of advanced thyroid cancer with targeted therapies: ten years of experience
D Viola, L Valerio, E Molinaro, L Agate… - Endocrine-related …, 2016 - erc.bioscientifica.com
Thyroid cancer is rare, but it is the most frequent endocrine malignancy. Its prognosis is
generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such …
generally favorable, especially in cases of well-differentiated thyroid cancers (DTCs), such …